173 related articles for article (PubMed ID: 21477701)
1. [Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database].
Almirante B
Med Clin (Barc); 2010 Dec; 135 Suppl 3():23-8. PubMed ID: 21477701
[TBL] [Abstract][Full Text] [Related]
2. [Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient].
Alvarez-Lerma F; Gracia-Arnillas MP
Med Clin (Barc); 2010 Dec; 135 Suppl 3():29-35. PubMed ID: 21477702
[TBL] [Abstract][Full Text] [Related]
3. [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)].
Lübbert C; Wilhelms D; Worlitzsch D; Ettrich TJ; Behl S; Seufferlein T
Z Gastroenterol; 2012 Apr; 50(4):373-81. PubMed ID: 22430297
[TBL] [Abstract][Full Text] [Related]
4. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
6. [Methodology and aims of the European Cubicin® Outcome Registry and Experience (EUCORE) database].
Rodríguez-Baño J
Med Clin (Barc); 2010 Dec; 135 Suppl 3():2-4. PubMed ID: 21477697
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
8. [The EUCORE registry: objectives and general results].
Cercenado E; Pachón J
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():3-9. PubMed ID: 22541969
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Owens RC; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Levine DP; Lamp KC
Am J Med; 2007 Oct; 120(10 Suppl 1):S28-33. PubMed ID: 17904948
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin in the treatment of bacteremia.
Sakoulas G; Golan Y; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S21-7. PubMed ID: 17904947
[TBL] [Abstract][Full Text] [Related]
12. [Safety of daptomycin in patients with renal impairment].
Azanza JR; Quetglas EG
Med Clin (Barc); 2010 Dec; 135 Suppl 3():55-9. PubMed ID: 21477705
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation.
Sakoulas G
Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():11-6. PubMed ID: 19917022
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin for the treatment of infective endocarditis: results from a European registry.
Dohmen PM; Guleri A; Capone A; Utili R; Seaton RA; González-Ramallo VJ; Pathan R; Heep M; Chaves RL
J Antimicrob Chemother; 2013 Apr; 68(4):936-42. PubMed ID: 23190763
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Mohr JF; Friedrich LV; Yankelev S; Lamp KC
Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
[TBL] [Abstract][Full Text] [Related]
16. [Daptomycin in diabetic patients].
Montejo M
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():54-8. PubMed ID: 22541977
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of daptomycin therapy in older adults with pluripathology].
Parra-Ruiz J; Hernández-Quero J
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():50-3. PubMed ID: 22541976
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
Grau S; Rebollo P; Cuervo J; Gil-Parrado S
Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
